[{"id":"ago-study-group","name":"AGO Study Group","tldr":"The AGO Study Group is the German gynaecological oncology trials group, founded in 1993 as AGO-OVAR to improve ovarian cancer treatment; it sponsors DESKTOP III and four other ovarian and vulvar cancer trials in OnCo.","route":"/companies/ago-study-group/","kind":"company","logo":"/logos/ago-study-group.png","avatar":"org","sub":"Wiesbaden, DE","facets":{"kind":["Company"],"cancers":["Ovarian cancer","High-grade serous ovarian cancer","Platinum-sensitive ovarian cancer","Vulvar cancer","HPV-associated vulvar squamous cell carcinoma","HPV-independent vulvar squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"High-grade serous ovarian cancer","href":"/cancers/high-grade-serous-ovarian-cancer/","tip":"High-grade serous cancer is the common, aggressive form of ovarian cancer, now known to start in the fallopian tube. It is treated with surgery and platinum chemotherapy, and maintenance PARP inhibitors have changed its course for the half of patients whose tumours cannot repair DNA properly."},{"label":"Platinum-sensitive ovarian cancer","href":"/cancers/platinum-sensitive-ovarian-cancer/","tip":"Platinum-sensitive ovarian cancer is disease that responded to carboplatin and either has not relapsed or relapses more than six months after the last dose. It is treated with further platinum chemotherapy, sometimes repeat surgery, and above all with maintenance PARP inhibitors, which keep BRCA-mutant tumours away for years and have raised long-term survival."},{"label":"Vulvar cancer","href":"/cancers/vulvar/","tip":"An uncommon cancer of the external genitalia with two distinct causes: HPV infection in younger women and chronic skin inflammation in older women. Surgery is the mainstay, and sentinel-node biopsy has made it far less mutilating."}],"tags":[]},"sortKeys":{"year":0}},{"id":"aids-malignancy-consortium","name":"AIDS Malignancy Consortium","tldr":"The AIDS Malignancy Consortium is the US National Cancer Institute-supported trials group for cancers in people with HIV, founded in 1995 with 38 sites worldwide; in OnCo it leads ANCHOR, the trial showing that treating anal precancer prevents anal cancer.","route":"/companies/aids-malignancy-consortium/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=amcoperations.com&sz=128","avatar":"org","sub":"United States (seat not stated), US","facets":{"kind":["Company"],"cancers":["Anal cancer","Anal high-grade squamous intraepithelial lesions"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Anal cancer","href":"/cancers/anal/","tip":"An HPV-caused cancer of the anal canal that is usually cured without surgery by combined chemotherapy and radiation. Prevention (HPV vaccination, screening of high-risk groups) and immunotherapy for advanced disease are the new fronts."},{"label":"Anal high-grade squamous intraepithelial lesions","href":"/cancers/anal-hsil-precursor/","tip":"Anal high-grade squamous intraepithelial lesions are the HPV-driven precancer that anal cancer grows from, found by screening people at high risk with cytology and high-resolution anoscopy. The ANCHOR trial showed that treating these lesions, mostly by ablation in the clinic, cuts the number that become anal cancer, so screening and treatment are now recommended for people living with HIV."}],"tags":[]},"sortKeys":{"year":0}},{"id":"aimery-de-gramont","name":"Aimery de Gramont","tldr":"Invented the FOLFOX regimen that anchors colorectal chemotherapy and founded the GERCOR and ARCAD trial groups.","route":"/people/aimery-de-gramont/","kind":"person","round":true,"avatar":"person","sub":"Head of Medical Oncology, Institut Hospitalier Franco-Britannique; Founder, GERCOR and ARCAD","facets":{"kind":["Person"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"tags":[{"label":"colorectal","href":"/tagged/colorectal/","tip":"Every record tagged colorectal."},{"label":"chemotherapy","href":"/tagged/chemotherapy/","tip":"Every record tagged chemotherapy."}]},"sortKeys":{"year":0}},{"id":"aio","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","tldr":"AIO is the medical oncology working group of the German Cancer Society, founded in 1976 with about 1,500 members; its trials company AIO-Studien-gGmbH sponsors the NALIRICC, NIFE and FLOT4 trials in OnCo and co-ran FIRE-3 and SSG XVIII.","route":"/companies/aio/","kind":"company","logo":"/logos/aio.png","avatar":"org","sub":"Berlin, DE","facets":{"kind":["Company"],"cancers":["Biliary tract cancer","Gallbladder cancer","Biliary tract cancer","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Oesophageal and junctional adenocarcinoma","Colorectal cancer","Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."},{"label":"Gallbladder cancer","href":"/cancers/gallbladder/","tip":"Gallbladder cancer starts in the small bile-storing sac under the liver and is one of the biliary tract cancers. Most cases are found late, or by chance when a gallbladder is removed for gallstones. It is rare in the UK, with about 1,300 cases a year, and much commoner in Chile, Bolivia and northern India. Found early, an operation can cure it."},{"label":"Biliary tract cancer","href":"/cancers/biliary-tract-cancer/","tip":"Biliary tract cancers arise in the bile ducts inside or outside the liver, the gallbladder or the ampulla where the duct meets the bowel. They share short survival and the same first-line chemotherapy with immunotherapy, but differ in causes and in the targetable mutations they carry. Each has its own page."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."}],"tags":[]},"sortKeys":{"year":0}},{"id":"alfa","name":"ALFA (Acute Leukemia French Association)","tldr":"ALFA is the French adult acute myeloid leukaemia cooperative group, an association founded in 1998 of clinicians, biologists and research assistants across 33 centres; in OnCo it leads ALFA-0701, the trial that brought gemtuzumab ozogamicin back.","route":"/companies/alfa/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=alfa-leukemia.org&sz=128","avatar":"org","sub":"France (seat not stated), FR","facets":{"kind":["Company"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"alliance-oncology","name":"Alliance for Clinical Trials in Oncology","tldr":"US cooperative group formed from CALGB, ACOSOG, and NCCTG; running OptimICE-pCR, which asks whether TNBC patients with a complete response still need a year of immunotherapy.","route":"/companies/alliance-oncology/","kind":"company","logo":"/logos/alliance-oncology.png","avatar":"org","sub":"Chicago, IL, US","facets":{"kind":["Company"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"andreas-du-bois","name":"Andreas du Bois","tldr":"Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer.","route":"/people/andreas-du-bois/","kind":"person","round":true,"avatar":"person","sub":"Director of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte; Chair, AGO Study Group · Kliniken Essen-Mitte","facets":{"kind":["Person"],"cancers":["Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"ovarian","href":"/tagged/ovarian/","tip":"Every record tagged ovarian."},{"label":"surgery","href":"/tagged/surgery/","tip":"Every record tagged surgery."}]},"sortKeys":{"year":0}},{"id":"anzup","name":"ANZUP Cancer Trials Group","tldr":"The Australian genitourinary trials group behind TheraP and proPSMA, the trials that put PSMA imaging and lutetium-PSMA therapy on the map.","route":"/companies/anzup/","kind":"company","logo":"/logos/anzup.png","avatar":"org","sub":"Sydney, AU","facets":{"kind":["Company"],"cancers":["Prostate cancer","Bladder & urothelial cancer","Renal cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Renal cell carcinoma","href":"/cancers/rcc/","tip":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}],"tags":[]},"sortKeys":{"year":0}},{"id":"arcagy-gineco","name":"ARCAGY-GINECO","tldr":"The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.","route":"/companies/arcagy-gineco/","kind":"company","logo":"/logos/arcagy-gineco.png","avatar":"org","sub":"Paris, FR","facets":{"kind":["Company"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"agitg","name":"Australasian Gastro-Intestinal Trials Group","tldr":"Australia and New Zealand's gastrointestinal cancer trials group, running practice-informing trials in gastric, oesophageal, colorectal and pancreatic cancer, including ctDNA-guided adjuvant studies.","route":"/companies/agitg/","kind":"company","logo":"/logos/agitg.png","avatar":"org","sub":"Sydney, AU","facets":{"kind":["Company"],"cancers":["Colorectal cancer","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Pancreatic ductal adenocarcinoma","Hepatocellular carcinoma","Neuroendocrine tumours"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[]},"sortKeys":{"year":0}},{"id":"abcsg","name":"Austrian Breast & Colorectal Cancer Study Group","tldr":"Austria's academic breast and colorectal trials group, whose bone-targeted and extended endocrine therapy trials changed breast cancer practice.","route":"/companies/abcsg/","kind":"company","logo":"/logos/abcsg.jpg","avatar":"org","sub":"Vienna, AT","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"tags":[]},"sortKeys":{"year":0}},{"id":"bradley-monk","name":"Bradley J. Monk","tldr":"Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment.","route":"/people/bradley-monk/","kind":"person","round":true,"avatar":"person","sub":"Gynecologic Oncologist, Florida Cancer Specialists; Professor, University of Arizona and Creighton University; Co-Director, GOG Partners","facets":{"kind":["Person"],"cancers":["Cervical cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."}],"tags":[{"label":"cervical","href":"/tagged/cervical/","tip":"Every record tagged cervical."},{"label":"ovarian","href":"/tagged/ovarian/","tip":"Every record tagged ovarian."}]},"sortKeys":{"year":0}},{"id":"breast-cancer-trials","name":"Breast Cancer Trials","tldr":"The Australian and New Zealand breast cancer trials group, a Breast International Group partner in SOFT/TEXT, APHINITY, OlympiA and POSITIVE.","route":"/companies/breast-cancer-trials/","kind":"company","logo":"/logos/breast-cancer-trials.png","avatar":"org","sub":"Newcastle, NSW, AU","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"big","name":"Breast International Group (BIG)","tldr":"The Breast International Group is the umbrella for 50+ academic breast cancer groups worldwide and co-sponsor of OlympiA, APHINITY, and HERA.","route":"/companies/big/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=bigagainstbreastcancer.org&sz=128","avatar":"org","sub":"Brussels, BE","facets":{"kind":["Company"],"cancers":["Triple-negative breast cancer","HER2-positive breast cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cctg","name":"Canadian Cancer Trials Group (CCTG)","tldr":"Canada's national academic trials group, which ran the CHALLENGE exercise trial and co-led the SABR-COMET oligometastasis trial.","route":"/companies/cctg/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=ctg.queensu.ca&sz=128","avatar":"org","sub":"Kingston, ON, CA","facets":{"kind":["Company"],"cancers":["Colorectal cancer","HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"cclg","name":"Children's Cancer and Leukaemia Group","tldr":"The UK and Ireland's professional body and trials network for children's cancer; nearly every child treated for cancer in the UK is cared for by a CCLG centre.","route":"/companies/cclg/","kind":"company","logo":"/logos/cclg.png","avatar":"org","sub":"Leicester, GB","facets":{"kind":["Company"],"cancers":["Acute lymphoblastic leukaemia","Neuroblastoma","Sarcomas","Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."},{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma is the hardest to treat: surgery, radiotherapy with temozolomide and tumour treating fields are its backbone, with CAR-T into the brain and focused ultrasound in trials."}],"tags":[]},"sortKeys":{"year":0}},{"id":"childrens-oncology-group","name":"Children's Oncology Group (COG)","tldr":"The Children's Oncology Group is the world's largest paediatric cancer trials organisation; most children with cancer in North America are treated on or according to a COG protocol.","route":"/companies/childrens-oncology-group/","kind":"company","logo":"/logos/childrens-oncology-group.png","avatar":"org","sub":"Monrovia, CA, US","facets":{"kind":["Company"],"cancers":["Acute lymphoblastic leukaemia","Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ctong","name":"Chinese Thoracic Oncology Group","tldr":"CTONG is the cooperative group of Chinese lung cancer trialists, founded by Yi-Long Wu, whose trials on EGFR-targeted pills before and after surgery changed practice worldwide.","route":"/companies/ctong/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=ctong.org.cn&sz=128","avatar":"org","sub":"Guangzhou, CN","facets":{"kind":["Company"],"cancers":["Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[{"label":"china","href":"/tagged/china/","tip":"Every record tagged china."}]},"sortKeys":{"year":0}},{"id":"christiane-pott","name":"Christiane Pott","tldr":"Kiel professor of medicine who serves as President of the German Lymphoma Alliance, the umbrella body for German lymphoma study groups, alongside co-president Georg Lenz.","route":"/people/christiane-pott/","kind":"person","round":true,"avatar":"person","sub":"President (Praesidentin) of the German Lymphoma Alliance · German Lymphoma Alliance","facets":{"kind":["Person"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"clinician-scientist","href":"/tagged/clinician-scientist/","tip":"Every record tagged clinician-scientist."},{"label":"haematology","href":"/tagged/haematology/","tip":"Every record tagged haematology."}]},"sortKeys":{"year":0}},{"id":"dahanca","name":"DAHANCA","tldr":"DAHANCA, the Danish Head and Neck Cancer Group established in September 1976, writes Denmark's head and neck cancer guidelines and ran the numbered DAHANCA radiotherapy trials, including DAHANCA 5 on the radiosensitiser nimorazole in OnCo.","route":"/companies/dahanca/","kind":"company","logo":"/logos/dahanca.png","avatar":"org","sub":"Denmark (seat not stated), DK","facets":{"kind":["Company"],"cancers":["Head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"tags":[]},"sortKeys":{"year":0}},{"id":"dbcg","name":"Danish Breast Cancer Group","tldr":"The Danish Breast Cancer Group, established by the Danish Surgical Society in 1976, writes Denmark's national breast cancer guidelines, keeps the national database and ran the DBCG 82b and 82c postmastectomy radiotherapy trials in OnCo.","route":"/companies/dbcg/","kind":"company","logo":"/logos/dbcg.png","avatar":"org","sub":"Copenhagen, DK","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"dpcg","name":"Dutch Pancreatic Cancer Group","tldr":"The Dutch Pancreatic Cancer Group is the national Dutch collaboration of pancreatic cancer surgeons, oncologists and researchers that ran PREOPANC, the trial that established neoadjuvant chemoradiotherapy for resectable pancreatic cancer.","route":"/companies/dpcg/","kind":"company","logo":"/logos/dpcg.png","avatar":"org","sub":"Amsterdam, NL","facets":{"kind":["Company"],"cancers":["Pancreatic ductal adenocarcinoma","Resectable pancreatic ductal adenocarcinoma","Borderline resectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Resectable pancreatic ductal adenocarcinoma","href":"/cancers/resectable-pdac/","tip":"Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."},{"label":"Borderline resectable pancreatic ductal adenocarcinoma","href":"/cancers/borderline-resectable-pdac/","tip":"Borderline resectable pancreatic cancer touches the big blood vessels behind the pancreas, so an operation straight away would probably leave cancer behind. Chemotherapy first, usually FOLFIRINOX for several months and sometimes radiotherapy, shrinks the edge of the tumour, and patients whose disease has not spread go on to surgery with a better chance of a clean removal."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ecog-acrin","name":"ECOG-ACRIN Cancer Research Group","tldr":"US cooperative group that pairs a therapy group with an imaging group; its E1910 trial moved blinatumomab into frontline leukaemia treatment.","route":"/companies/ecog-acrin/","kind":"company","logo":"/logos/ecog-acrin.png","avatar":"org","sub":"Philadelphia, PA, US","facets":{"kind":["Company"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[]},"sortKeys":{"year":0}},{"id":"curie-nki-eortc","name":"EORTC","tldr":"EORTC is Europe's academic cancer trials organisation and has run practice-changing trials since 1962.","route":"/companies/curie-nki-eortc/","kind":"company","logo":"/logos/curie-nki-eortc.jpg","avatar":"org","sub":"Brussels, BE","facets":{"kind":["Company"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[],"tags":[]},"sortKeys":{"year":0}},{"id":"etop-ibcsg","name":"ETOP IBCSG Partners Foundation","tldr":"The Bern-based foundation that unites the International Breast Cancer Study Group (SOFT, TEXT, POSITIVE) and the European Thoracic Oncology Platform.","route":"/companies/etop-ibcsg/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=ibcsg.org&sz=128","avatar":"org","sub":"Bern, CH","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Non-small-cell lung cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[]},"sortKeys":{"year":0}},{"id":"european-myeloma-network","name":"European Myeloma Network","tldr":"The European Myeloma Network is the non-profit network of European myeloma haematologists created from 2005 to run shared research and trials; its Dutch foundation is the registry sponsor of CARTITUDE-6 in OnCo.","route":"/companies/european-myeloma-network/","kind":"company","logo":"/logos/european-myeloma-network.png","avatar":"org","sub":"Rotterdam, NL","facets":{"kind":["Company"],"cancers":["Multiple myeloma","Newly diagnosed multiple myeloma, transplant-eligible"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Newly diagnosed multiple myeloma, transplant-eligible","href":"/cancers/myeloma-transplant-eligible/","tip":"Fit patients with newly diagnosed myeloma receive four drugs at once, then their own stem cells are collected, they are given high-dose chemotherapy, the cells are returned and they continue on maintenance. Adding the CD38 antibody daratumumab to the three-drug backbone, tested in PERSEUS and CASSIOPEIA, means most patients now reach a state where no myeloma can be detected."}],"tags":[]},"sortKeys":{"year":0}},{"id":"filo","name":"FILO (French Innovative Leukemia Organisation)","tldr":"FILO is the French cooperative group for leukaemia trials, with its registered office in the haematology department of the Tours university hospital; in OnCo it leads a phase 2 trial of eltrombopag in older patients with acute myeloid leukaemia.","route":"/companies/filo/","kind":"company","logo":"/logos/filo.png","avatar":"org","sub":"Tours, FR","facets":{"kind":["Company"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[]},"sortKeys":{"year":0}},{"id":"fondazione-italiana-linfomi","name":"Fondazione Italiana Linfomi","tldr":"The Fondazione Italiana Linfomi is Italy's non-profit lymphoma trials foundation, constituted in 2010 out of the Intergruppo Italiano Linfomi of 1994 and working with more than 150 Italian centres; in OnCo it leads two lymphoma trials.","route":"/companies/fondazione-italiana-linfomi/","kind":"company","logo":"/logos/fondazione-italiana-linfomi.png","avatar":"org","sub":"Alessandria, IT","facets":{"kind":["Company"],"cancers":["Non-Hodgkin lymphoma","Follicular lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Non-Hodgkin lymphoma","href":"/cancers/non-hodgkin-lymphoma/","tip":"Non-Hodgkin lymphoma is not one disease but a family of more than sixty cancers of the lymphocytes, the white blood cells of the immune system. About 95 per cent come from B cells and the rest from T or NK cells; some grow over years and are watched, others grow over weeks and are treated to cure. The family is the map; the subtype is the disease, and the subtype is what decides the treatment."},{"label":"Follicular lymphoma","href":"/cancers/follicular-lymphoma/","tip":"Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."}],"tags":[]},"sortKeys":{"year":0}},{"id":"french-sarcoma-group","name":"French Sarcoma Group","tldr":"The French Sarcoma Group is the national cooperative group for soft tissue and bone sarcoma trials in France; in OnCo it is the sponsor of ANGIOTAX and the group behind LMS-04 and CABONE.","route":"/companies/french-sarcoma-group/","kind":"company","avatar":"org","sub":"France (seat not stated), FR","facets":{"kind":["Company"],"cancers":["Sarcomas","Angiosarcoma","Vascular tumours","Leiomyosarcoma","Uterine sarcoma","Soft tissue sarcoma of the extremity","Retroperitoneal sarcoma","Osteosarcoma","Ewing sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Angiosarcoma","href":"/cancers/angiosarcoma/","tip":"Angiosarcoma is an aggressive vascular tumour, a cancer of the cells that line blood and lymph vessels. It grows as bruise-like patches on the scalp of older people, in breasts treated years earlier with radiotherapy, or inside organs. Surgery and radiotherapy are used where possible, weekly paclitaxel is the most active drug, and immunotherapy helps a minority with the sun-damaged scalp form."},{"label":"Vascular tumours","href":"/cancers/vascular-tumours/","tip":"Vascular tumours range from angiosarcoma, an aggressive cancer of blood vessel lining cells, to the slow-growing EHE and the infant tumour KHE. Angiosarcoma responds to paclitaxel and, in the sun-damaged scalp form, to immunotherapy; EHE and KHE depend on growth signals that the mTOR blocker sirolimus quiets, and EHE without symptoms is watched."},{"label":"Leiomyosarcoma","href":"/cancers/leiomyosarcoma/","tip":"Leiomyosarcoma is a cancer of smooth muscle, most often in the womb, the abdomen behind the bowel or the wall of a large vein. Surgery is the only cure; for spread disease, doxorubicin-based chemotherapy, trabectedin and gemcitabine-docetaxel are the standards, with no targeted drug yet."}],"tags":[]},"sortKeys":{"year":0}},{"id":"geicam","name":"GEICAM Spanish Breast Cancer Group","tldr":"Spain's national breast cancer research group, running adjuvant chemotherapy, endocrine and CDK4/6 inhibitor trials across more than 200 hospitals.","route":"/companies/geicam/","kind":"company","logo":"/logos/geicam.png","avatar":"org","sub":"Madrid, ES","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gercor","name":"GERCOR","tldr":"GERCOR is a French non-profit cooperative group created in 1997 that sponsors its own phase 2 and 3 solid tumour trials through a network of about 300 investigators; in OnCo it leads LAP07 in locally advanced pancreatic cancer.","route":"/companies/gercor/","kind":"company","logo":"/logos/gercor.png","avatar":"org","sub":"Paris, FR","facets":{"kind":["Company"],"cancers":["Pancreatic ductal adenocarcinoma","Locally advanced unresectable pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Locally advanced unresectable pancreatic ductal adenocarcinoma","href":"/cancers/locally-advanced-pdac/","tip":"Locally advanced pancreatic cancer has grown around the arteries or veins behind the pancreas so that it cannot be removed, but it has not spread to other organs. Chemotherapy is the main treatment, joined in 2026 by a device that delivers electric fields to the tumour; radiotherapy controls pain and local growth, and a minority of tumours shrink enough to be operated on after all."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gbg","name":"German Breast Group (GBG)","tldr":"The German academic group whose GeparX trials established carboplatin and neoadjuvant strategies in triple-negative breast cancer.","route":"/companies/gbg/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=gbg.de&sz=128","avatar":"org","sub":"Neu-Isenburg, DE","facets":{"kind":["Company"],"cancers":["Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"german-cll-study-group","name":"German CLL Study Group","tldr":"The German CLL Study Group, founded in 1996 at the University of Cologne, runs the numbered CLL trials that set first-line treatment of chronic lymphocytic leukaemia, including CLL12, CLL13 (GAIA) and CLL14 in OnCo.","route":"/companies/german-cll-study-group/","kind":"company","logo":"/logos/german-cll-study-group.png","avatar":"org","sub":"Cologne, DE","facets":{"kind":["Company"],"cancers":["Chronic lymphocytic leukaemia","Chronic lymphocytic leukaemia, first treatment","Leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Chronic lymphocytic leukaemia, first treatment","href":"/cancers/cll-treatment-naive/","tip":"Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."},{"label":"Leukaemia","href":"/cancers/leukaemia/","tip":"Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ghsg","name":"German Hodgkin Study Group","tldr":"The Cologne-based group whose HD trials, from BEACOPP to BrECADD in HD21, have set the standard for treating Hodgkin lymphoma for four decades.","route":"/companies/ghsg/","kind":"company","logo":"/logos/ghsg.png","avatar":"org","sub":"Cologne, DE","facets":{"kind":["Company"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"german-lymphoma-alliance","name":"German Lymphoma Alliance","tldr":"Germany's aggressive lymphoma trials group, formerly DSHNHL, whose MInT, RICOVER-60 and FLYER trials set how many cycles of R-CHOP patients need.","route":"/companies/german-lymphoma-alliance/","kind":"company","logo":"/logos/german-lymphoma-alliance.png","avatar":"org","sub":"Homburg, DE","facets":{"kind":["Company"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gimema","name":"GIMEMA","tldr":"Italy's adult haematology trials group, famous for making acute promyelocytic leukaemia curable without chemotherapy and for chemotherapy-free Philadelphia-positive ALL.","route":"/companies/gimema/","kind":"company","logo":"/logos/gimema.png","avatar":"org","sub":"Rome, IT","facets":{"kind":["Company"],"cancers":["Acute myeloid leukaemia","Acute lymphoblastic leukaemia","Chronic lymphocytic leukaemia","Multiple myeloma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gog-foundation","name":"GOG Foundation","tldr":"The US gynaecologic oncology trials organisation whose GOG-3000-series trials with industry brought immunotherapy into endometrial and cervical cancer.","route":"/companies/gog-foundation/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=gog.org&sz=128","avatar":"org","sub":"Philadelphia, PA, US","facets":{"kind":["Company"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[]},"sortKeys":{"year":0}},{"id":"gortec","name":"GORTEC","tldr":"GORTEC is the French head and neck radiotherapy and oncology group, an association founded in 1999 that runs the academic trials behind much of the standard of care in head and neck cancer, including TPExtreme and NIVOPOSTOP in OnCo.","route":"/companies/gortec/","kind":"company","logo":"/logos/gortec.jpg","avatar":"org","sub":"Tours, FR","facets":{"kind":["Company"],"cancers":["Head and neck squamous cell carcinoma","Recurrent or metastatic head and neck squamous cell carcinoma","HPV-negative head and neck squamous cell carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Recurrent or metastatic head and neck squamous cell carcinoma","href":"/cancers/recurrent-metastatic-hnscc/","tip":"When head and neck cancer comes back where it cannot be removed, or spreads elsewhere, it is treated to extend life rather than cure: pembrolizumab, alone or with chemotherapy, is the first choice, cetuximab-based regimens and cheap oral chemotherapy are alternatives, and antibodies that hit two targets at once are in late-stage trials."},{"label":"HPV-negative head and neck squamous cell carcinoma","href":"/cancers/hpv-negative-head-and-neck-cancer/","tip":"Head and neck cancers caused by tobacco and alcohol rather than HPV are harder to cure: surgery or cisplatin chemoradiation is the mainstay, immunotherapy given around surgery (KEYNOTE-689) or after it (NIVOPOSTOP) has begun to help, and pembrolizumab is the first treatment once the disease has spread."}],"tags":[]},"sortKeys":{"year":0}},{"id":"horg","name":"Hellenic Oncology Research Group","tldr":"The Hellenic Oncology Research Group is a Greek non-profit of oncologists and scientists that runs its own cancer trials; in OnCo it leads three phase 3 adjuvant breast cancer trials.","route":"/companies/horg/","kind":"company","logo":"/logos/horg.png","avatar":"org","sub":"Athens, GR","facets":{"kind":["Company"],"cancers":["Breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Breast cancer","href":"/cancers/breast-cancer/","tip":"Breast cancer is not one disease, and the result that decides which page you need is the receptor result: whether the cancer carries oestrogen and progesterone receptors, and whether it carries too much HER2. Those two answers give four boxes, not three, with a page for each. Grade and stage do not change which page you read; they change what happens on it."}],"tags":[]},"sortKeys":{"year":0}},{"id":"hovon","name":"HOVON","tldr":"The Dutch-Belgian adult haematology trials group, one of Europe's largest engines of leukaemia, myeloma and lymphoma phase 3 trials.","route":"/companies/hovon/","kind":"company","logo":"/logos/hovon.jpg","avatar":"org","sub":"Rotterdam, NL","facets":{"kind":["Company"],"cancers":["Acute myeloid leukaemia","Multiple myeloma","Diffuse large B-cell lymphoma","Chronic lymphocytic leukaemia","Hodgkin lymphoma","Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ignace-vergote","name":"Ignace Vergote","tldr":"Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer.","route":"/people/ignace-vergote/","kind":"person","round":true,"avatar":"person","sub":"Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT · UZ Leuven / Leuven Cancer Institute","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"ovarian","href":"/tagged/ovarian/","tip":"Every record tagged ovarian."},{"label":"cervical","href":"/tagged/cervical/","tip":"Every record tagged cervical."},{"label":"adc","href":"/tagged/adc/","tip":"Every record tagged adc."}]},"sortKeys":{"year":0}},{"id":"itcc","name":"Innovative Therapies for Children with Cancer (ITCC)","tldr":"Europe's network of children's hospitals that run the first trials of new cancer drugs in children, so that European children can access experimental medicines close to home.","route":"/companies/itcc/","kind":"company","logo":"/logos/itcc.png","avatar":"org","sub":"Villejuif, FR","facets":{"kind":["Company"],"cancers":["Neuroblastoma","Diffuse midline glioma, H3 K27-altered","Paediatric low-grade glioma","Rhabdomyosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."},{"label":"Diffuse midline glioma, H3 K27-altered","href":"/cancers/dipg-dmg/","tip":"Diffuse midline glioma grows through the brainstem and cannot be removed surgically. A single change in a histone protein (H3 K27M) rewires how the tumour reads its DNA. Radiotherapy was long the only help; in 2025 the first drug aimed at this tumour, dordaviprone (ONC201), was approved after durable shrinkage in some patients, and GD2 CAR-T cells have produced striking early responses."},{"label":"Paediatric low-grade glioma","href":"/cancers/paediatric-low-grade-glioma/","tip":"Paediatric low-grade gliomas are slow-growing brain tumours driven almost always by a single overactive signal, the MAPK pathway, most often through a BRAF gene change. Because the switch is known, pills that block it (dabrafenib with trametinib, and tovorafenib) now shrink tumours far more often than chemotherapy, and children are increasingly spared radiation to the developing brain."},{"label":"Rhabdomyosarcoma","href":"/cancers/rhabdomyosarcoma/","tip":"A childhood soft-tissue sarcoma, a cancer of muscle-like cells found anywhere from the eye socket to the bladder. Most children are cured with chemotherapy, surgery and radiation, and a fusion gene (PAX-FOXO1) now decides how intensively to treat."}],"tags":[{"label":"paediatric","href":"/tagged/paediatric/","tip":"Every record tagged paediatric."}]},"sortKeys":{"year":0}},{"id":"ifct","name":"Intergroupe Francophone de Cancérologie Thoracique","tldr":"The French thoracic oncology intergroup, which ran the national Biomarkers France programme showing that routine molecular testing of lung cancer improves survival.","route":"/companies/ifct/","kind":"company","logo":"/logos/ifct.jpg","avatar":"org","sub":"Paris, FR","facets":{"kind":["Company"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer. About a third of cases are confined to one side of the chest and are treated to cure with chemotherapy and radiotherapy together; the rest respond to chemotherapy and relapse quickly. After 30 years without progress, durvalumab consolidation, the T-cell engager tarlatamab and antibody-drug conjugates have each lengthened survival since 2024."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ifm","name":"Intergroupe Francophone du Myélome (IFM)","tldr":"The IFM is the French-speaking myeloma cooperative group created in 1994, with 140 French and 33 Belgian centres, whose trials set melphalan-autograft intensification, bortezomib induction and lenalidomide maintenance; in OnCo it leads CASSIOPEIA and IFM 2009.","route":"/companies/ifm/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=myelome.fr&sz=128","avatar":"org","sub":"Paris, FR","facets":{"kind":["Company"],"cancers":["Multiple myeloma","Newly diagnosed multiple myeloma, transplant-eligible"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Newly diagnosed multiple myeloma, transplant-eligible","href":"/cancers/myeloma-transplant-eligible/","tip":"Fit patients with newly diagnosed myeloma receive four drugs at once, then their own stem cells are collected, they are given high-dose chemotherapy, the cells are returned and they continue on maintenance. Adding the CD38 antibody daratumumab to the three-drug backbone, tested in PERSEUS and CASSIOPEIA, means most patients now reach a state where no myeloma can be detected."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ielsg","name":"International Extranodal Lymphoma Study Group","tldr":"A Swiss-based international group that runs the trials defining treatment of rare extranodal lymphomas, including primary CNS lymphoma and gastric MALT lymphoma.","route":"/companies/ielsg/","kind":"company","logo":"/logos/ielsg.png","avatar":"org","sub":"Bellinzona, CH","facets":{"kind":["Company"],"cancers":["Diffuse large B-cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"tags":[]},"sortKeys":{"year":0}},{"id":"italian-sarcoma-group","name":"Italian Sarcoma Group","tldr":"The Italian Sarcoma Group is the Italian non-profit collaborative group for soft tissue, GIST and bone sarcoma research, constituted in June 1997; in OnCo it leads ISG-STS 1001, the histology-tailored neoadjuvant chemotherapy trial.","route":"/companies/italian-sarcoma-group/","kind":"company","logo":"/logos/italian-sarcoma-group.png","avatar":"org","sub":"Bologna, IT","facets":{"kind":["Company"],"cancers":["Sarcomas","Soft tissue sarcoma of the extremity","Undifferentiated pleomorphic sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Soft tissue sarcoma of the extremity","href":"/cancers/extremity-soft-tissue-sarcoma/","tip":"Most soft tissue sarcomas arise in an arm or leg. Limb-saving surgery with radiotherapy cures most localised tumours and is as safe as amputation. For spread disease doxorubicin is the backbone: adding ifosfamide shrinks more tumours without lengthening life, and in leiomyosarcoma adding trabectedin doubles the time the disease stays controlled."},{"label":"Undifferentiated pleomorphic sarcoma","href":"/cancers/undifferentiated-pleomorphic-sarcoma/","tip":"Undifferentiated pleomorphic sarcoma is the diagnosis for a high-grade soft tissue sarcoma whose cells show no recognisable line of differentiation. It is treated with surgery and radiotherapy, with doxorubicin-based chemotherapy for high-risk or spread disease, and it is one of the few sarcomas in which the immunotherapy drug pembrolizumab has clear activity."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jcog","name":"Japan Clinical Oncology Group (JCOG)","tldr":"JCOG is Japan's national cooperative group and defines surgical and perioperative standards in gastric and oesophageal cancer.","route":"/companies/jcog/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=jcog.jp&sz=128","avatar":"org","sub":"Tokyo, JP","facets":{"kind":["Company"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"jeffrey-dome","name":"Jeffrey S. Dome","tldr":"Led the COG renal tumour committee that used biology to tailor Wilms tumour treatment.","route":"/people/jeffrey-dome/","kind":"person","round":true,"avatar":"person","sub":"Senior Vice President, Center for Cancer and Blood Disorders, Children's National Hospital, Washington DC · Children's National Hospital","facets":{"kind":["Person"],"cancers":["Wilms tumour"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Wilms tumour","href":"/cancers/wilms-tumor/","tip":"Wilms tumour is a kidney cancer of young children and one of paediatric oncology's success stories: surgery plus a few months of chemotherapy cures about nine in ten. Today's trials aim to give the lowest-risk children almost no chemotherapy while finding the few with aggressive biology."}],"tags":[{"label":"paediatric","href":"/tagged/paediatric/","tip":"Every record tagged paediatric."},{"label":"wilms-tumor","href":"/tagged/wilms-tumor/","tip":"Every record tagged wilms-tumor."}]},"sortKeys":{"year":0}},{"id":"kara-kelly","name":"Kara M. Kelly","tldr":"Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease.","route":"/people/kara-kelly/","kind":"person","round":true,"avatar":"person","sub":"Chair of Pediatric Oncology, Roswell Park Comprehensive Cancer Center; Division Chief, Pediatric Hematology/Oncology, University at Buffalo · Roswell Park Comprehensive Cancer Center","facets":{"kind":["Person"],"cancers":["Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[{"label":"paediatric","href":"/tagged/paediatric/","tip":"Every record tagged paediatric."},{"label":"hodgkin","href":"/tagged/hodgkin/","tip":"Every record tagged hodgkin."}]},"sortKeys":{"year":0}},{"id":"kcsg","name":"Korean Cancer Study Group","tldr":"South Korea's multicentre cooperative trials group, linking the Seoul mega-hospitals and regional centres in investigator-initiated trials in gastric, lung, liver and breast cancer.","route":"/companies/kcsg/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=kcsg.org&sz=128","avatar":"org","sub":"Seoul, KR","facets":{"kind":["Company"],"cancers":["Gastric & gastro-oesophageal junction cancer","Non-small-cell lung cancer","Hepatocellular carcinoma","HER2-positive breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."}],"tags":[]},"sortKeys":{"year":0}},{"id":"kgog","name":"Korean Gynecologic Oncology Group","tldr":"The Korean Gynecologic Oncology Group is the Korean incorporated association that runs gynaecological cancer trials; in OnCo it leads a phase 2 study of progestin with a levonorgestrel intrauterine system for fertility-sparing treatment of early endometrial cancer.","route":"/companies/kgog/","kind":"company","logo":"/logos/kgog.png","avatar":"org","sub":"Seoul, KR","facets":{"kind":["Company"],"cancers":["Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"linda-mileshkin","name":"Linda Mileshkin","tldr":"Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result.","route":"/people/linda-mileshkin/","kind":"person","round":true,"avatar":"person","sub":"Medical Oncologist and Director of Clinical Trials, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre","facets":{"kind":["Person"],"cancers":["Cervical cancer","Cancer of unknown primary"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Cancer of unknown primary","href":"/cancers/cancer-of-unknown-primary/","tip":"Cancer found already spread, where doctors cannot find where it started. Genomic profiling finds a drug target in about a third of cases and tumour-agnostic approvals apply directly; the rest still rely on general-purpose chemotherapy, which is what those tests are changing."}],"tags":[{"label":"cervical","href":"/tagged/cervical/","tip":"Every record tagged cervical."},{"label":"australia","href":"/tagged/australia/","tip":"Every record tagged australia."}]},"sortKeys":{"year":0}},{"id":"lysa","name":"LYSA (The Lymphoma Study Association)","tldr":"The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.","route":"/companies/lysa/","kind":"company","logo":"/logos/lysa.png","avatar":"org","sub":"Pierre-Bénite (Lyon), FR","facets":{"kind":["Company"],"cancers":["Diffuse large B-cell lymphoma","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[]},"sortKeys":{"year":0}},{"id":"martin-dreyling","name":"Martin Dreyling","tldr":"Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.","route":"/people/martin-dreyling/","kind":"person","round":true,"avatar":"person","sub":"Professor of Medicine and Head of the Lymphoma Program, LMU University Hospital Munich; Chair, European MCL Network · LMU Klinikum München","facets":{"kind":["Person"],"cancers":["Mantle cell lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Mantle cell lymphoma","href":"/cancers/mantle-cell-lymphoma/","tip":"An uncommon B-cell lymphoma driven by cyclin D1 that used to behave badly in almost everyone. BTK inhibitors, CAR-T and now BCL2 drugs have changed it from chemotherapy-plus-transplant to targeted combinations."}],"tags":[{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."},{"label":"mantle-cell","href":"/tagged/mantle-cell/","tip":"Every record tagged mantle-cell."}]},"sortKeys":{"year":0}},{"id":"mrc-ctu","name":"MRC Clinical Trials Unit at UCL","tldr":"The MRC Clinical Trials Unit at UCL is the UK public trials unit that designed and ran STAMPEDE, FOCUS4, ICON7 and UKCTOCS; it marked 25 years in 2024 and became the UCL Innovative Clinical Trials Unit in April 2026.","route":"/companies/mrc-ctu/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=mrcctu.ucl.ac.uk&sz=128","avatar":"org","sub":"London, GB","facets":{"kind":["Company"],"cancers":["Prostate cancer","Metastatic hormone-sensitive prostate cancer","Localised prostate cancer, high and very high risk","Colorectal cancer","Ovarian cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Metastatic hormone-sensitive prostate cancer","href":"/cancers/prostate-mhspc/","tip":"Metastatic hormone-sensitive prostate cancer is disease that has spread but still responds to lowering testosterone. Hormone therapy alone is no longer enough: adding an androgen receptor inhibitor, and docetaxel for high-volume disease, lengthens life by years."},{"label":"Localised prostate cancer, high and very high risk","href":"/cancers/prostate-high-risk/","tip":"High-risk prostate cancer has Grade Group 4 or 5 disease, a PSA above 20 or a tumour growing beyond the gland. It is still curable, but needs radiotherapy with two to three years of hormone therapy, or surgery followed by radiotherapy, and adding abiraterone to hormone therapy now lengthens life in the highest-risk men."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nicola-gokbuget","name":"Nicola Gökbuget","tldr":"Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL.","route":"/people/nicola-gokbuget/","kind":"person","round":true,"avatar":"person","sub":"Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt · University Cancer Center Frankfurt (UCT)","facets":{"kind":["Person"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[{"label":"all","href":"/tagged/all/","tip":"Every record tagged all."},{"label":"mrd","href":"/tagged/mrd/","tip":"Every record tagged mrd."}]},"sortKeys":{"year":0}},{"id":"nordic-lymphoma-group","name":"Nordic Lymphoma Group","tldr":"The Danish, Finnish, Norwegian, Swedish and Icelandic lymphoma trials network, best known for the Nordic mantle cell lymphoma regimen.","route":"/companies/nordic-lymphoma-group/","kind":"company","logo":"/logos/nordic-lymphoma-group.jpg","avatar":"org","sub":"Stockholm, SE","facets":{"kind":["Company"],"cancers":["Diffuse large B-cell lymphoma","Hodgkin lymphoma","Chronic lymphocytic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nrg-oncology","name":"NRG Oncology","tldr":"The US cooperative group formed from the radiation, gynaecologic, and breast trial groups; it co-led OlympiA, the trial that put a PARP inhibitor after surgery for BRCA carriers.","route":"/companies/nrg-oncology/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=nrgoncology.org&sz=128","avatar":"org","sub":"Philadelphia, PA, US","facets":{"kind":["Company"],"cancers":["Triple-negative breast cancer","Prostate cancer","Cervical cancer","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"nsabp-foundation","name":"NSABP Foundation","tldr":"The legacy US surgical adjuvant trials group that proved lumpectomy equals mastectomy, tamoxifen prevents breast cancer and trastuzumab cures more HER2-positive disease.","route":"/companies/nsabp-foundation/","kind":"company","logo":"/logos/nsabp-foundation.png","avatar":"org","sub":"Pittsburgh, PA, US","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ocog","name":"Ontario Clinical Oncology Group","tldr":"The Ontario Clinical Oncology Group is a Canadian academic trials group based at the Juravinski Hospital in Hamilton that designs and runs investigator-led cancer trials; in OnCo it leads LUMINA, the radiotherapy-omission study in low-risk luminal A breast cancer.","route":"/companies/ocog/","kind":"company","logo":"https://www.google.com/s2/favicons?domain=ocog.ca&sz=128","avatar":"org","sub":"Hamilton, Ontario, CA","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"richard-stone","name":"Richard M. Stone","tldr":"Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML.","route":"/people/richard-stone/","kind":"person","logo":"/portraits/richard-stone.jpg","round":true,"avatar":"person","sub":"Chief of Staff and Director of Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center","facets":{"kind":["Person"],"cancers":["Acute myeloid leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute myeloid leukaemia","href":"/cancers/aml/","tip":"Acute myeloid leukaemia is an aggressive blood cancer where, after 40 years of the same chemotherapy, a wave of targeted drugs (FLT3, IDH, BCL-2, menin) arrived."}],"tags":[{"label":"aml","href":"/tagged/aml/","tip":"Every record tagged aml."},{"label":"flt3","href":"/tagged/flt3/","tip":"Every record tagged flt3."}]},"sortKeys":{"year":0}},{"id":"rolf-stahel","name":"Rolf A. Stahel","tldr":"Founded the European Thoracic Oncology Platform and leads the merged ETOP IBCSG academic trials foundation.","route":"/people/rolf-stahel/","kind":"person","round":true,"avatar":"person","sub":"President, ETOP IBCSG Partners Foundation; Emeritus Professor of Oncology, University of Zurich · ETOP IBCSG Partners Foundation","facets":{"kind":["Person"],"cancers":["Non-small-cell lung cancer","Mesothelioma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Mesothelioma","href":"/cancers/mesothelioma/","tip":"An asbestos-caused cancer of the lung lining. Immunotherapy doublets replaced chemotherapy in 2020, and mesothelin CAR-T is under study."}],"tags":[{"label":"thoracic","href":"/tagged/thoracic/","tip":"Every record tagged thoracic."},{"label":"europe","href":"/tagged/europe/","tip":"Every record tagged europe."}]},"sortKeys":{"year":0}},{"id":"ruth-ladenstein","name":"Ruth Ladenstein","tldr":"Chaired the SIOPEN HR-NBL1 trial, the largest neuroblastoma trial ever, which set European standards for high-risk disease.","route":"/people/ruth-ladenstein/","kind":"person","round":true,"avatar":"person","sub":"Professor of Paediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna · St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)","facets":{"kind":["Person"],"cancers":["Neuroblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Neuroblastoma","href":"/cancers/neuroblastoma/","tip":"Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."}],"tags":[{"label":"paediatric","href":"/tagged/paediatric/","tip":"Every record tagged paediatric."},{"label":"neuroblastoma","href":"/tagged/neuroblastoma/","tip":"Every record tagged neuroblastoma."}]},"sortKeys":{"year":0}},{"id":"sarc","name":"SARC (Sarcoma Alliance for Research through Collaboration)","tldr":"SARC is a US non-profit sarcoma research organisation founded in 2003 by sarcoma physicians at five medical centres to run collaborative trials; in OnCo it leads SARC028, the pembrolizumab study across sarcoma subtypes.","route":"/companies/sarc/","kind":"company","logo":"/logos/sarc.png","avatar":"org","sub":"Ann Arbor, Michigan, US","facets":{"kind":["Company"],"cancers":["Sarcomas","Undifferentiated pleomorphic sarcoma","Liposarcoma","Osteosarcoma","Ewing sarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."},{"label":"Undifferentiated pleomorphic sarcoma","href":"/cancers/undifferentiated-pleomorphic-sarcoma/","tip":"Undifferentiated pleomorphic sarcoma is the diagnosis for a high-grade soft tissue sarcoma whose cells show no recognisable line of differentiation. It is treated with surgery and radiotherapy, with doxorubicin-based chemotherapy for high-risk or spread disease, and it is one of the few sarcomas in which the immunotherapy drug pembrolizumab has clear activity."},{"label":"Liposarcoma","href":"/cancers/liposarcoma/","tip":"Liposarcoma is a cancer of fat cells that comes in four different forms: two driven by extra copies of the MDM2 gene, one by a fusion gene that makes it unusually sensitive to radiotherapy and trabectedin, and one that behaves like other aggressive sarcomas. Surgery is the mainstay and MDM2 inhibitors are the most promising drugs in trials."},{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[]},"sortKeys":{"year":0}},{"id":"scandinavian-sarcoma-group","name":"Scandinavian Sarcoma Group","tldr":"The Scandinavian Sarcoma Group, formed in 1979 by Nordic sarcoma physicians and scientists, writes shared treatment protocols and ran SSG XVIII, the trial that set three years of adjuvant imatinib for high-risk GIST.","route":"/companies/scandinavian-sarcoma-group/","kind":"company","logo":"/logos/scandinavian-sarcoma-group.jpg","avatar":"org","sub":"Lund, SE","facets":{"kind":["Company"],"cancers":["Sarcomas"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Sarcomas","href":"/cancers/sarcoma/","tip":"Sarcomas are dozens of rare cancers of bone and connective tissue. GIST was the first solid tumour cured-in-practice by a targeted pill; synovial sarcoma got the first TCR-T therapy."}],"tags":[]},"sortKeys":{"year":0}},{"id":"sebastien-armanet","name":"Sébastien Armanet","tldr":"Director General who runs the operational team of ARCAGY-GINECO, the French non-profit academic research group for gynaecological and metastatic breast cancers.","route":"/people/sebastien-armanet/","kind":"person","round":true,"avatar":"person","sub":"Directeur Général (Director General) of ARCAGY-GINECO · ARCAGY-GINECO","facets":{"kind":["Person"],"cancers":["Ovarian cancer","Endometrial cancer","Cervical cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"clinical-trials","href":"/tagged/clinical-trials/","tip":"Every record tagged clinical-trials."}]},"sortKeys":{"year":0}},{"id":"sirpa-leppa","name":"Sirpa Leppä","tldr":"Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries.","route":"/people/sirpa-leppa/","kind":"person","round":true,"avatar":"person","sub":"Chairperson, Nordic Lymphoma Group · Nordic Lymphoma Group","facets":{"kind":["Person"],"cancers":["Diffuse large B-cell lymphoma","Hodgkin lymphoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."},{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."}],"tags":[{"label":"leadership","href":"/tagged/leadership/","tip":"Every record tagged leadership."},{"label":"clinician-scientist","href":"/tagged/clinician-scientist/","tip":"Every record tagged clinician-scientist."},{"label":"lymphoma","href":"/tagged/lymphoma/","tip":"Every record tagged lymphoma."}]},"sortKeys":{"year":0}},{"id":"solti","name":"SOLTI Cancer Research Group","tldr":"A Barcelona-based academic breast cancer group known for biomarker-driven trials that use PAM50 intrinsic subtypes to pick therapy.","route":"/companies/solti/","kind":"company","logo":"/logos/solti.png","avatar":"org","sub":"Barcelona, ES","facets":{"kind":["Company"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"stefan-bielack","name":"Stefan S. Bielack","tldr":"Leads the COSS group and co-led EURAMOS-1, the largest osteosarcoma trial ever run.","route":"/people/stefan-bielack/","kind":"person","round":true,"avatar":"person","sub":"Head of Paediatric Oncology, Klinikum Stuttgart Olgahospital; Chair, Cooperative Osteosarcoma Study Group · Klinikum Stuttgart / Olgahospital","facets":{"kind":["Person"],"cancers":["Osteosarcoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Osteosarcoma","href":"/cancers/osteosarcoma/","tip":"Osteosarcoma is the most common bone cancer, mostly in teenagers. Chemotherapy plus surgery cures about two-thirds when it has not spread; because no new drug has beaten that chemotherapy in a large trial in 30 years, the next gains are being sought in cellular therapy against GD2, HER2 and B7-H3."}],"tags":[{"label":"paediatric","href":"/tagged/paediatric/","tip":"Every record tagged paediatric."},{"label":"osteosarcoma","href":"/tagged/osteosarcoma/","tip":"Every record tagged osteosarcoma."}]},"sortKeys":{"year":0}},{"id":"stephen-hunger","name":"Stephen P. Hunger","tldr":"Chaired the COG leukaemia committee through the era that pushed childhood ALL cure rates above 90%.","route":"/people/stephen-hunger/","kind":"person","round":true,"avatar":"person","sub":"Chief, Division of Oncology, Children's Hospital of Philadelphia; Jeffrey E. Perelman Distinguished Chair in Pediatrics · Children's Hospital of Philadelphia","facets":{"kind":["Person"],"cancers":["Acute lymphoblastic leukaemia"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Person","tip":"The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."}],"tags":[{"label":"paediatric","href":"/tagged/paediatric/","tip":"Every record tagged paediatric."},{"label":"all","href":"/tagged/all/","tip":"Every record tagged all."}]},"sortKeys":{"year":0}},{"id":"swog","name":"SWOG Cancer Research Network","tldr":"SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.","route":"/companies/swog/","kind":"company","logo":"/logos/swog.png","avatar":"org","sub":"Portland, OR, US","facets":{"kind":["Company"],"cancers":["Hodgkin lymphoma","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Hodgkin lymphoma","href":"/cancers/hodgkin-lymphoma/","tip":"Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"trog","name":"TROG Cancer Research","tldr":"The Australian and New Zealand radiation oncology trials group, which has run practice-changing trials of hypofractionation, stereotactic radiotherapy and radiation-drug combinations.","route":"/companies/trog/","kind":"company","logo":"/logos/trog.png","avatar":"org","sub":"Newcastle, NSW, AU","facets":{"kind":["Company"],"cancers":["Prostate cancer","Non-small-cell lung cancer","Head and neck squamous cell carcinoma","Endometrial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."}],"tags":[]},"sortKeys":{"year":0}},{"id":"unicancer","name":"UNICANCER","tldr":"UNICANCER is the network of France's comprehensive cancer centres and its academic trials sponsor.","route":"/companies/unicancer/","kind":"company","logo":"/logos/unicancer.svg","avatar":"org","sub":"Paris, FR","facets":{"kind":["Company"],"cancers":["Colorectal cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"wjog","name":"West Japan Oncology Group","tldr":"Japan's second national cooperative group, born in thoracic oncology; its WJTOG3405 trial helped establish EGFR inhibitors as first-line lung cancer therapy.","route":"/companies/wjog/","kind":"company","logo":"/logos/wjog.png","avatar":"org","sub":"Osaka, JP","facets":{"kind":["Company"],"cancers":["Non-small-cell lung cancer","Small-cell lung cancer","Gastric & gastro-oesophageal junction cancer","Colorectal cancer","HER2-positive breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Company","tip":"Who is building what."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Small-cell lung cancer","href":"/cancers/sclc/","tip":"A fast-growing lung cancer. About a third of cases are confined to one side of the chest and are treated to cure with chemotherapy and radiotherapy together; the rest respond to chemotherapy and relapse quickly. After 30 years without progress, durvalumab consolidation, the T-cell engager tarlatamab and antibody-drug conjugates have each lengthened survival since 2024."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"tags":[]},"sortKeys":{"year":0}}]